Abstract
SummaryCOVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report that administration of an updated monovalent mRNA vaccine (XBB.1.5 MV) to uninfected individuals boosted serum virus-neutralization antibodies significantly against not only XBB.1.5 (27.0-fold) and the currently dominant EG.5.1 (27.6-fold) but also key emergent viruses like HV.1, HK.3, JD.1.1, and JN.1 (13.3-to-27.4-fold). In individuals previously infected by an Omicron subvariant, serum neutralizing titers were boosted to highest levels (1,504-to-22,978) against all viral variants tested. While immunological imprinting was still evident with the updated vaccines, it was not nearly as severe as the previously authorized bivalent BA.5 vaccine. Our findings strongly support the official recommendation to widely apply the updated COVID-19 vaccines to further protect the public.
Publisher
Cold Spring Harbor Laboratory
Reference30 articles.
1. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
2. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies;Nature,2020
3. SARS-CoV-2 variant biology: immune escape, transmission and fitness;Nat Rev Microbiol,2023
4. Chalkias, S. , McGhee, N. , Whatley, J.L. , Essink, B. , Brosz, A. , Tomassini, J.E. , Girard, B. , Wu, K. , Edwards, D.K. , Nasir, A. , et al. (2023). Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines. medRxiv, 2023.2008.2022.23293434.
5. Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters;N Engl J Med,2023